Radiomics in prostate cancer: an up-to-date review

: Prostate cancer (PCa) is the most common worldwide diagnosed malignancy in male population. The diagnosis, the identification of aggressive disease, and the post-treatment follow-up needs a more comprehensive and holistic approach. Radiomics is the extraction and interpretation of images phenotypes in a quantitative manner. Radiomics may give an advantage through advancements in imaging modalities and through the potential power of artificial intelligence techniques by translating those features into clinical outcome prediction. This article gives an overview on the current evidence of methodology and reviews the available literature on radiomics in PCa patients, highlighting its potential for personalized treatment and future applications

Prostate cancer radiogenomics—from imaging to molecular characterization

Radiomics and genomics represent two of the most promising fields of cancer research, designed to improve the risk stratification and disease management of patients with prostate cancer (PCa). Radiomics involves a conversion of imaging derivate quantitative features using manual or automated algorithms, enhancing existing data through mathematical analysis. This could increase the clinical value in PCa management. To extract features from imaging methods such as magnetic resonance imaging (MRI), the empiric nature of the analysis using machine learning and artificial intelligence could help make the best clinical decisions. Genomics information can be explained or decoded by radiomics. The development of methodologies can create more-efficient predictive models and can better characterize the molecular features of PCa. Additionally, the identification of new imaging biomarkers can overcome the known heterogeneity of PCa, by non-invasive radio-logical assessment of the whole specific organ. In the future, the validation of recent findings, in large, randomized cohorts of PCa patients, can establish the role of radiogenomics. Briefly, we aimed to review the current literature of highly quantitative and qualitative results from well-de-signed studies for the diagnoses, treatment, and follow-up of prostate cancer, based on radiomics, genomics and radiogenomics research

Biparametric prostate MRI: impact of a deep learning-based software and of quantitative ADC values on the inter-reader agreement of experienced and inexperienced readers

Objective To investigate the impact of an artificial intelligence (AI) software and quantitative ADC (qADC) on the inter-reader agreement, diagnostic performance, and reporting times of prostate biparametric MRI (bpMRI) for experienced and inexperienced readers. Materials and methods A total of 170 multiparametric MRI (mpMRI) of patients with suspicion of prostate cancer (PCa) were retrospectively reviewed by one experienced and one inexperienced reader three times, following a wash-out period. First, only the bpMRI sequences, including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI) sequences, and apparent diffusion coefficient (ADC) maps, were used. Then, bpMRI and quantitative ADC values were used. Lastly, bpMRI and the AI software were used. Inter-reader agreement between the two readers and between each reader and the mpMRI original reports was calculated. Detection rates and reporting times were calculated for each group. Results Inter-reader agreement with respect to mpMRI was moderate for bpMRI, Quantib, and qADC for both the inexperienced (weighted k of 0.42, 0.45, and 0.41, respectively) and the experienced radiologists (weighted k of 0.44, 0.46, and 0.42, respectively). Detection rate of PCa was similar between the inexperienced (0.24, 0.26, and 0.23) and the experienced reader (0.26, 0.27 and 0.27), for bpMRI, Quantib, and qADC, respectively. Reporting times were lower for Quantib (8.23, 7.11, and 9.87 min for the inexperienced reader and 5.62, 5.07, and 6.21 min for the experienced reader, for bpMRI, Quantib, and qADC, respectively). Conclusions AI and qADC did not have a significant impact on the diagnostic performance of both readers. The use of Quantib was associated with lower reporting times

Entwicklung einer Radiomics-Signatur sowie eines Deep Learning Algorithmus für die Prädiktion von signifikanten Prostatakarzinomen

Das Prostatakarzinom (PCa) ist weltweit die häufigste maligne Tumorerkrankung und die zweithäufigste tumorbezogene Todesursache des Mannes. Die Diskrepanz zwischen hoher Inzidenz und Prävalenz und niedriger Mortalität begründet die Notwendigkeit, sicher zwischen klinisch signifikanten und indolenten PCa zu differenzieren. Bisherige Diagnosemethoden gewährleisten nicht in ausreichendem Maße die präzise Charakterisierung. Durch die Anwendung von Radiomics zusammen mit künstlicher Intelligenz (KI), i.e. Machine Learning, an multiparametrischen MRT (mpMRT) sollen Prädiktionen zur klinischen Signifikanz von PCa möglich werden. Hierzu wurden die Schritte einer Radiomics- bzw. Machine Learning-Pipeline an mpMRT von 297 Patienten durchgeführt. Die Support Vector Machine (SVM) erbrachte bei der Klassifikation in „benigne Läsion“ oder „PCa“ eine AUC = 0,86. Es wurden zusätzlich ein zonaler Radiomics- und ein Deep Learning-Ansatz exploriert. Der zonale Ansatz erbrachte im Vergleich zum nicht-zonalen Ansatz schlechtere Ergebnisse (AUC = 0,75). Beim Deep Learning-Klassifikationssystem wurde ein Sequence-Model angewandt (AUC = 0,81, vs. PI-RADS: AUC = 0,77). Diese Studie zeigt, dass aus mpMRT prädiktive Radiomics Features abgeleitet werden können, und kann dazu beitragen, eine zuverlässige Radiomics-Signatur und einen Machine Learning- bzw. Deep Learning-Algorithmus zur Prädiktion signifikanter PCa für den klinischen Alltag zu entwickeln

Radiomic and genomic machine learning method performance for prostate cancer diagnosis : systematic literature review

Background Machine learning algorithms have been drawing attention at the joining of pathology and radiology in prostate cancer research. However, due to their algorithmic learning complexity and the variability of their architecture, there is an ongoing need to analyze their performance. Objective This study assesses the source of heterogeneity and the performance of machine learning applied to radiomic, genomic, and clinical biomarkers for the diagnosis of prostate cancer. One research focus of this study was on clearly identifying problems and issues related to the implementation of machine learning in clinical studies. Methods Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) protocol, 816 titles were identified from the PubMed, Scopus, and OvidSP databases. Studies that used machine learning to detect prostate cancer and provided performance measures were included in our analysis. The quality of the eligible studies was assessed using the QUADAS-2 (quality assessment of diagnostic accuracy studies–version 2) tool. The hierarchical multivariate model was applied to the pooled data in a meta-analysis. To investigate the heterogeneity among studies, I2 statistics were performed along with visual evaluation of coupled forest plots. Due to the internal heterogeneity among machine learning algorithms, subgroup analysis was carried out to investigate the diagnostic capability of machine learning systems in clinical practice. Results In the final analysis, 37 studies were included, of which 29 entered the meta-analysis pooling. The analysis of machine learning methods to detect prostate cancer reveals the limited usage of the methods and the lack of standards that hinder the implementation of machine learning in clinical applications. Conclusions The performance of machine learning for diagnosis of prostate cancer was considered satisfactory for several studies investigating the multiparametric magnetic resonance imaging and urine biomarkers; however, given the limitations indicated in our study, further studies are warranted to extend the potential use of machine learning to clinical settings. Recommendations on the use of machine learning techniques were also provided to help researchers to design robust studies to facilitate evidence generation from the use of radiomic and genomic biomarkers

Deep learning for an improved diagnostic pathway of prostate cancer in a small multi-parametric magnetic resonance data regime

Prostate Cancer (PCa) is the second most commonly diagnosed cancer among men, with an estimated incidence of 1.3 million new cases worldwide in 2018. The current diagnostic pathway of PCa relies on prostate-specific antigen (PSA) levels in serum. Nevertheless, PSA testing comes at the cost of under-detection of malignant lesions and a substantial over-diagnosis of indolent ones, leading to unnecessary invasive testing such biopsies and treatment in indolent PCa lesions. Magnetic Resonance Imaging (MRI) is a non-invasive technique that has emerged as a valuable tool for PCa detection, staging, early screening, treatment planning and intervention. However, analysis of MRI relies on expertise, can be time-consuming, requires specialized training and in its absence suffers from inter and intra-reader variability and sub-optimal interpretations. Deep Learning (DL) techniques have the ability to recognize complex patterns in imaging data and are able to automatize certain assessments or tasks while offering a lesser degree of subjectiveness, providing a tool that can help clinicians in their daily tasks. In spite of it, DL success has traditionally relied on the availability of large amounts of labelled data, which are rarely available in the medical field and are costly and hard to obtain due to privacy regulations of patients’ data and required specialized training, among others. This work investigates DL algorithms specially tailored to work in a limited data regime with the final objective of improving the current prostate cancer diagnostic pathway by improving the performance of DL algorithms for PCa MRI applications in a limited data regime scenario. In particular, this thesis starts by exploring Generative Adversarial Networks (GAN) to generate synthetic samples and their effect on tasks such as prostate capsule segmentation and PCa lesion significance classification (triage). Following, we explore the use of Auto-encoders (AEs) to exploit the data imbalance that is usually present in medical imaging datasets. Specifically, we propose a framework based on AEs to detect the presence of prostate lesions (tumours) by uniquely learning from control (healthy) data in an outlier detection-like fashion. This thesis also explores more recent DL paradigms that have shown promising results in natural images: generative and contrastive self-supervised learning (SSL). In both cases, we propose specific prostate MRI image manipulations for a PCa lesion classification downstream task and show the improvements offered by the techniques when compared with other initialization methods such as ImageNet pre-training. Finally, we explore data fusion techniques in order to leverage different data sources in the form of MRI sequences (orthogonal views) acquired by default during patient examinations and that are commonly ignored in DL systems. We show improvements in a PCa lesion significance classification when compared to a single input system (axial view)